Aug 14, 2023 / 12:30PM GMT
Frank Candido -
Good morning. Welcome to the SHARE Series Monday Management Update. I am Frank Candido, and I have the pleasure of speaking with Kenneth d'Entremont, CEO at Medexus; and Marcel Konrad, CFO at Medexus. (Operator Instructions) Ken?
Kenneth d'Entremont - Medexus Pharmaceuticals Inc. - CEO & Director
Thank you, Frank. Thank you for the opportunity to present Medexus here to you this morning. Medexus is traded on the TSX under the ticker symbol, MDP, and on the OTCQX, under the ticker symbol MEDXF.
I will just go to the next slide, please.
This is our forward-looking statement. Our forward-looking statement can be found on our website at medexus.com, along with lots of other useful information for investors.
Let's go to the next slide, and we'll start to describe the company.
In a nutshell, Medexus is a commercially focused pharma company, with over $100 million in revenue, producing over $16 million in positive EBITDA. We're very much focused on the commercial aspects of the business. We're not an R
Medexus Pharmaceuticals Inc at Openexchange Share Series (Virtual) Transcript
Feb 14, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers